Department of Dermatology, Hallym University Sacred Heart Hospital, Anyang, Korea.
Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
J Korean Med Sci. 2022 Jul 11;37(27):e211. doi: 10.3346/jkms.2022.37.e211.
Omalizumab is a very important drug for the treatment of chronic urticaria. Although omalizumab's therapeutic efficacy has been demonstrated, data on real-world experiences in Korea, especially regarding chronic inducible urticaria (CIndU), are limited. This study attempted to compare the efficacy of omalizumab in Korean chronic spontaneous urticaria (CSU) and CIndU patients.
Fifty-two CSU and 29 CIndU patients were included and Urticaria Activity Score 7 (UAS7) at baseline, week 4, and week 12 was assessed retrospectively.
Omalizumab 150 mg significantly decreased UAS7 in both patients with CSU and CIndU with only one dose ( < 0.001). The significant decrease in the UAS7 scores of both groups of patients continued from weeks 4 to 12. Although there was no significant difference in treatment efficacy between the two groups, the symptoms of patients with CSU tended to improve faster; furthermore, the number of antihistamines administered daily reduced more significantly in this patient group ( = 0.047). Additionally, the decrease in the UAS7 score between baseline and week 12 and the response rate were higher in patients with CSU.
Omalizumab may be slightly more effective against CSU than against CIndU. Regarding the CIndU subtypes, dermatographic urticaria was associated with the greatest reduction in the UAS7 score, and patients with this condition showed the highest response rate, indicating the best effect of omalizumab. The duration of chronic urticaria was greater in non-responders than in responders ( = 0.025). Conversely, baseline immunoglobulin E levels were significantly higher in responders ( = 0.039).
奥马珠单抗是治疗慢性荨麻疹的重要药物。虽然奥马珠单抗的疗效已得到证实，但韩国真实世界经验的数据，特别是关于慢性诱导性荨麻疹（CIndU）的数据有限。本研究试图比较奥马珠单抗在韩国慢性自发性荨麻疹（CSU）和 CIndU 患者中的疗效。
共纳入 52 例 CSU 和 29 例 CIndU 患者，回顾性评估基线、第 4 周和第 12 周的荨麻疹活动评分 7 分（UAS7）。
奥马珠单抗 150mg 单次治疗即可显著降低 CSU 和 CIndU 患者的 UAS7（<0.001）。两组患者的 UAS7 评分从第 4 周持续下降至第 12 周。虽然两组患者的治疗效果无显著差异，但 CSU 患者的症状改善速度较快；此外，该患者组每日给予的抗组胺药数量减少更为显著（=0.047）。此外，CSU 患者的 UAS7 评分从基线至第 12 周的下降幅度和应答率更高。
奥马珠单抗对 CSU 的疗效可能略优于 CIndU。对于 CIndU 亚型，皮肤划痕性荨麻疹 UAS7 评分下降幅度最大，且该类患者的应答率最高，表明奥马珠单抗的疗效最佳。无应答者的慢性荨麻疹持续时间长于应答者（=0.025）。相反，应答者的基线免疫球蛋白 E 水平显著更高（=0.039）。
